Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科學和Assembly Biosciences宣佈了爲期12年的抗病毒療法合作伙伴關係，最初的重點是Assembly Bio的皰疹病毒、乙型肝炎病毒和丁型肝炎病毒；Assembly Bio將獲得1億美元的預付款
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科學公司、Assembly Biosciences公司宣佈了為期12年的抗病毒治療合作夥伴關係，最初的重點是Assembly Bio公司的皰疹病毒、乙肝病毒和丁型肝炎病毒；Assembly Bio公司將獲得1億美元的預付款
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。